ArticleJournal of neurology2025
Guidelines adherence in status epilepticus first steps treatment: factors associated with non-compliance and effect on outcome.
Article in Journal of neurology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Treatment adequacy outweighs treatment sequence in non-convulsive status epilepticus.Epilepsia · 2026Article
- Benzodiazepines versus non-benzodiazepine antiseizure medications as first-line agents for status epilepticus: analysis of real word data from a 9-years prospective cohort.Frontiers in neurology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveWe investigate adherence to acute-phase treatment guidelines for status epilepticus (SE) in a university and a community hospital, assessing factors influencing compliance and its impact on SE duration and outcomes.
methodsWe retrospectively analyzed two prospective cohorts, including 452 adults with SE (excluding post-anoxic SE). Adherence was defined as administration of a correctly dosed benzodiazepine (BZD) as first-line therapy, followed by a non-sedative antiseizure medication (ASM) as second-line treatment. We examined associations between adherence, clinical and demographic factors, and discharge outcomes.
resultsOnly 129/452 (29%) patients received guideline-adherent treatment. A treatment delay > 1 h (p = 0.03) was the only factor significantly associated with non-adherence. Among 323 non-adherent treatment, 283 (89%) received a BZD, but only 66 (28%) at the correct dose. Older age, decreased consciousness, and pre-existing epilepsy influenced BZD treatment patterns. Adherence to treatment sequence did not affect clinical outcomes, but SE duration was significantly shorter in patients treated per guidelines (272 vs. 880 min, p = 0.0003).
conclusionsAdherence to SE treatment guidelines remains low. Guideline-based treatment shortens SE duration but does not significantly impact discharge outcomes. While age, history of epilepsy and consciousness disorders influence BZD use, the lack of clear predictors of overall adherence suggests possible gaps in guideline awareness among healthcare providers.
Indexed as
Identifiers
40890518What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.